Antiageing and Life Enhancement Pharmacotherapeutics

Facets of normal chronological ageing and lifestyle contribute to a diverse group of highly prevalent conditions that are associated with physiological or psychological deficits or symptoms of sufficient severity which compel an individual to seek medical attention to restore, alter, or improve undesired aspects of body image, physical function, or wellbeing. The conditions are wide-ranging and comprise the four major medical specialty areas of dermatology, psychiatry, reproductive health and sexual disorders, which collectively include 10 major therapy areas, some of which are alopecia, cutaneous ageing, depressive illnesses, addictions, contraception, infertility, and erectile dysfunction.

Antiageing and life enhancement therapy areas are poised for dramatic expansion over the next decade driven by factors such as increasing worldwide ageing populations, unrelenting media fixation on physical improvement and restorative antiageing treatments, and innovation in the pharmaceutical industry to bring to market highly sophisticated efficacious drug treatments that serve to close the gap between medical and cosmetic interventions. Research and development investment in the specialty area is unfaltering with over 180 companies collectively investing more than US$5 billion in the hope to capitalize on a dynamic pipeline of 275 drug candidates that are currently progressing through to the clinic. Although the capital risks are high in the antiageing and life enhacement R&D arena, the potential returns on investment are vast in a market currently estimated at US$36 billion and predicted to rise to US$49 billion by 2012, and over US$100 billion by 2020.

New drug indications combined with next generation molecules and compounds will transform the landscape of how physicians treat disorders associated with ageing or lifestyle. Current drugs are being developed with multiple therapeutic benefits that will be able to treat several ailments through single dosing. Drugs on the horizon indicated for obesity, for example, also display secondary benefits for patients with coexisting diabetes and dyslipidaemia in addition to crossover indications for tobacco addiction. in this instance the interrelation of metabolic diseases can be improved by one drug alone as opposed to three potential drug medications, a facet that will revolutionize drug treatment regimens for patients, particularly those with high cardiovascular disease risk profiles where coexisting obesity, diabetes and smoking increase disease susceptibility. Moreover, novel drugs that alter body composition or effect changes in functional aspects of daily living are anticipated to not only change the armamentarium of medical treatments in the antiageing domain but also alter the 2006 Spectra Intelligence. All rights reserved.

medical perceptions of antiageing and life-enhancement treatments. Novel pharmacotherapeutics may redefine treatment paradigms allowing physicians the capacity to impede or rejuvenate internal physiological ageing mechanisms or halt deleterious effects caused by lifestyle activities. Pharmacological innovation in the field may even prove beneficial in the prevention of illnesses associated with traditional drug development areas, such as in musculoskeletal disease, cancer and neurodegenerative diseases due to therapeutic synergies and shared drug targets that underly salient pathophysiological mechanisms. in short, the antiageing and life enhancement specialty area is evolving into an exciting, innovative and highly dynamic discipline. Based on current trends, it is expected that the therapy areas will flourish offering a myriad of new drug treatment options for a range of conditions that are currently poorly served with high unmet needs.

in This Report Entitled Antiageing and Life Enhancement Pharmacotherapeutics:

Rejuvenating Drug Markets to 2012 and beyond, the reader will be introduced to a specialty pharmaceutical market that is transitioning to a high-growth, high-value prospect. The scope of the report encompasses up-to-date coverage of epidemiological, aetiological, and demographic data related to ageing and lifestyle disorders. Furthermore, market insights are provided by way of extensive sector analyses of marketed and newly launched products, pipeline drugs, and companyactivities, in addition to comment on strategic and commercial issues that may affect product positioning and revenue optimization. The report also discusses key prospects that have the potential to create new market sectors and become blockbuster products over the next decade.

Chapter 1 provides an overview of the antiageing and life enhancement domain and outlines the extent of the therapy areas and how they are categorized, classified, and characterized. This chapter also provides a comprehensive account of prevalence statistics, pathophysiology, treatment methods, and the types of pharmacotherapies currently available to combat symptoms of ageing and impairments that are related to lifestyle dysfunction.

An in-depth evaluation of dermatological conditions related to ageing and lifestyle is presented in Chapter 2. Therapy areas include alopecia, cutaneous ageing, pigmentation disorders, and the lipodermal areas of obesity and lipodystrophy. The chapter provides a detailed analysis of the sector to include insights for product extension and optimization, sales forecasts to 2012, and impact of late-stage pipeline 2006 Spectra Intelligence. All rights reserved. drugs on the market. Each therapy area segment concludes with a summary of the key issues that are considered to affect growth and sustainability.

Report Highlights and Key Findings

• Data-intensive multipart tome on the state of the US$36bn antiageing and life enhancement drug market
• in-depth market research and analysis of over 15 market sectors and subsectors
• Comprehensive review of epidemiological, aetiological and therapeutic data for over 40 disorders
• Sales estimates (US$) to 2012 for over 90 key products
• Therapy forecasting for 10 specialty areas (US$)
• Strategic insights for life-cycle optimization and product development
• Evaluation of leading products and major competitors
• Identified emerging growth markets with high-revenue yielding prospects
• Recognized market drivers and inhibitors in the specialty pharma sector
• Trend analysis of industry events and activities over the past 2 years
• Detailed R&D themes and clusters by therapy area
• Data generation on sector and market values between 2004-2012 and predictions to 2020 (US$)

Reasons to Purchase This Report

• Qualitative assessment of current disorder characteristics, definitions, including aetiological and epidemiological data
• Comprehensive update on antiageing and life enhancement drugs sector
• in-depth analysis and discussion on the pathophysiology and prevalence of the main ageing and lifestyle disorders, including alopecia, cutaneous ageing, pigmentations conditions, obesity, depressive illnesses, addictions, sleep disorders, cognitive and memory impairments, contraception, infertility, and sexual disorders
• Provides unrivalled insight into the development of antiageing and life enhancement drugs and emerging market opportunities
• Market value predictions by therapy area and for individual marketed products to 2012
• Quantitative analysis of marketed drugs and impact of new close-to-market candidates and pipeline products
• Insight into potential blockbusters and super-blockbusters of the future
• Illustrates the importance and need for antiageing and lifestyle medicines over the next 20 years
• Provides extensive coverage of R&D pipelines of key players in the sector
• Shows proprietary market modelling for prospect analysis across 15 main therapy areas.

What Can Be Learnt from This Report?

• How are antiageing and lifestyle conditions defined and characterized?
• What are the therapeutic benefits of antiageing and lifestyle drugs?
• What are the main areas of antiageing and lifestyle drug development?
• What criteria are involved in creating blockbuster antiageing and life enhancement drugs?
• What is the impact of global ageing in lifestyle drug development?
• What are the prevalence rates of ageing conditions and lifestyle disorders globally?
• What factors are shaping the future of antiageing and lifestyle drug drug development?
• What are the current market values for antiageing and life enhancement drugs and what will be the market value of this sector by 2012?
• What are the emerging market opportunities for antiageing drugs?
• What are the emerging market opportunities for life enhancement drugs?
• Which therapeutic areas are identified for high-value growth?
• Who are the main players in the antiageing and life enhancement domain?
• Which companies are developing antiageing and life enhancement drugs?
• Which antiageing and lifestyle drug development therapeutic areas are research intensive and which are not?
• Which therapy areas are saturated and which represent niche market opportunities?
• What is the future outlook for marketed antiageing and lifestyle drugs and for those in development?
• What is the prediction for the global markets by 2020?
• What are the top prospects in the development pipeline for antiageing and life enhancement therapy sectors?